l e t t e r s
Insertional mutagenesis in a haploid background can disrupt gene function 1 . We extend our earlier work by using a retroviral gene-trap vector to generate insertions in >98% of the genes expressed in a human cancer cell line that is haploid for all but one of its chromosomes. We apply phenotypic interrogation via tag sequencing (PhITSeq) to examine millions of mutant alleles through selection and parallel sequencing. Analysis of pools of cells, rather than individual clones 1 enables rapid assessment of the spectrum of genes involved in the phenotypes under study. This facilitates comparative screens as illustrated here for the family of cytolethal distending toxins (CDTs). CDTs are virulence factors secreted by a variety of pathogenic Gramnegative bacteria responsible for tissue damage at distinct anatomical sites 2 . We identify 743 mutations distributed over 12 human genes important for intoxication by four different CDTs. Although related CDTs may share host factors, they also exploit unique host factors to yield a profile characteristic for each CDT.
The ability to remove or inactivate single genes in cells or intact organisms has revolutionized all aspects of modern biology. Gene disruption in human cells is hampered by their diploid nature, the inability to set up genetic crosses at will and low rates of homologous recombination. As a result, only very few human traits have been subjected to detailed mutagenesis-based analyses using conventional methods. We recently developed a screening approach based on gene inactivation in human cells using insertional mutagenesis in the KBM7 chronic myeloid leukemia cell line, which is haploid for all chromosomes except chromosome 8 (ref. 1) . However, this required that individual clones be isolated, expanded and used for DNA isolation to map genetrap insertions by inverse-PCR and Sanger sequencing. Such screens are labor intensive, do not necessarily reach saturation and thus may not produce a reliable genome-wide overview of genes that contribute to phenotypes of interest.
To overcome these shortcomings, we report here how deep sequencing can be used to interrogate millions of mutant alleles and assign genes to phenotypes with high saturation and accuracy.
Analogous to recent developments in high-density insertional mutagenesis in microorganisms [3] [4] [5] , this approach may enable the comparison of mutant phenotypes under different conditions. We first benchmarked a large population of mutagenized cells by examining mutation frequencies in individual genes by deep sequencing. We then used this benchmarked population of mutant cells for 12 independent phenotypic selections. As inferred from the number of independent insertions in genes of interest in a given screen, we achieved a high level of saturation and thus a genome-wide overview of the genes involved. Finally, we applied these technological advances to four comparative genome-wide screens, using toxins secreted by Gram-negative bacteria as the selecting agents. We could distinguish among toxins produced by related pathogens that evolved to affect different anatomical sites in the human body. These comparative screens identified with high confidence ten host factors not previously implicated in intoxication and furthermore provide evidence that these structurally and functionally related, yet distinct, toxins evolved to exploit distinct sets of host factors to achieve intoxication of their hosts.
To obtain accurate genome-wide overviews of genes involved in particular phenotypes, we increased the saturation of gene-trap mutagenesis in two ways. First, for a given screen, we increased the total number of cells infected with a promoterless retroviral gene-trap vector to 100 million cells and improved the retroviral transduction rate to ~75%. Second, in an improvement over our earlier approach 1 , we aimed to retain insertion events also in genes that are silent or that show low or heterogeneous expression. Typically, mutagenesis by promoter-trap vectors involves a selection step for insertions into active genes by tracking the reporter gene embedded in the gene trap. We omitted this step and characterized the mutagenized cell pool without selection, thereby extending the mutagenized cell population to include gene-trap insertions, into silent genes and heterogeneously or not highly expressed genes, as well as insertions in the orientation opposite to direction of transcription. To characterize the extent and type of insertions obtained in our mutagenized cell population, we mapped the flanking sequences of ~900,000 independent insertion sites. We did this by using a linear amplification mediated-PCR Global gene disruption in human cells to assign genes to phenotypes by deep sequencing l e t t e r s (LAM-PCR), followed by single-stranded (ss)DNA linker ligation and massively parallel sequencing (Supplementary Table 1) .
Insertion sites were distributed over all chromosomes but were biased toward genes, because ~49% of the insertions were present within RefSeq-annotated genes (Supplementary Table 2 ). These insertions covered ~70% of all RefSeq genes. On average, each gene contains ~30 independent insertions. Although we did not select a priori for active genes by using the selection embedded in the genetrap vector, it is known that gammaretroviral insertion sites have a preference for genomic regions near histone marks that are positively associated with transcription 6 . To assess the extent of mutagenesis obtained, we compared our mapped insertion database with expression data in KBM7 cells 7 . Ninety-eight percent of the genes classified as expressed based on KBM7 microarray data (Supplementary Table 3 ) contain at least one gene-trap insertion. These percentages decrease to 90% for marginally expressed genes and to 65% for genes classified as nonexpressed. Given that we sequenced only ~1% of the mutations present in the input cell population (0.9 million out of the 75 million mutants), we conclude that our full library contains many independent mutations in nearly all expressed genes, including those expressed at low levels and for the majority of genes that are hetero geneously expressed or silent under basal growth conditions. Phenotypic selection of mutant cells, followed by mapping of the mutations in the selected pool, should therefore yield a detailed genome-wide view of the genetic components associated with a particular phenotype. We call this approach PhITSeq.
As a first screening experiment, we exposed 100 million mutagenized cells to a recently developed antagonist of the anti-apoptotic BCL-2 family, the small molecule ABT-737 (ref. 8) , which induces regression of solid tumors. We confirmed that, before selection, the unselected population of mutagenized cells contains mutations in all main components of the apoptotic machinery ( Supplementary  Fig. 1 ). After selection, cells were expanded and sequences flanking the insertion sites were amplified using an inverse-PCR protocol, followed by massively parallel sequencing. These sequences were then mapped to the human genome and for each insertion the distances to its closest neighboring, independent insertions were determined. This allowed the calculation of a proximity index for each insertion. A high numerical value for this index represents a short distance to its neighbors (Fig. 1a,b) . Because passenger mutations will be randomly distributed over the genome, these should have a low proximity index, whereas driver mutations are expected to cluster closely in distinct genomic regions and should have a high proximity index. After ABT-737 selection of the mutant pool, we observed two regions on chromosome 18 and 19 with a high density of insertions (Fig. 1b) . These regions show a combined total of 117 independent mutations distributed over regions encoding the genes NOXA and BAX. Clonally derived cell lines that contain gene-trap insertions in these genes show loss of expression of the corresponding gene (Fig. 1c) . Both pro-apoptotic proteins have been implicated in ABT-737-mediated induction of cell death 9, 10 .
PhITSeq couples the abundance of independent insertional mutations to a phenotype. We do not select for inactivating mutations a priori: our mutant library contains insertions in introns in both the sense (thereby inactivating the gene) and antisense (not likely to inactivate a gene when inserted in intronic sequences) orientations. As viral integration in the sense or antisense orientation is a random event, a skewed distribution of insertions in a particular gene is indicative of selection, and a functional consequence of inactivation. Indeed, when we compare the collections of insertions in cells that survive selection, there is strong enrichment of the inactivating sense mutations. As a graphic illustration of this point, we chose a gene for l e t t e r s which the largest number of insertions was identified (Fig. 1d ). In our screen for resistance to diphtheria toxin, we disrupted the gene that encodes the entry receptor of diphtheria toxin receptor (HBEGF, 295 independent insertions). Whereas sense and antisense insertions are present in equal proportions in the unselected starting collection of mutant cells, the antisense insertions in introns are almost completely lost from the selected survivors. The remaining antisense insertions are located mainly within exonic sequences of the gene and are therefore likely to be mutagenic as well. Thus, PhITSeq accurately links inactivating mutations to a phenotype of interest and is not dependent on prior knowledge or gene annotation.
Our second screening experiment involved identifying host factors required for the effects of bacterial toxins. Cytolethal distending toxins (CDTs) are secreted by multiple bacterial species that cause disease 2 , including food borne diseases (Escherichia coli, Shigella dysenteriae, Campylobacter jejuni and Salmonella typhi), aggressive periodontitis (Aggregatibacter actinomycetemcomitans) and sexually transmitted disease (Haemophilus ducreyi). Their CDTs have been proposed to be virulence factors and are further suspected of having carcinogenic properties because the catalytic subunit of these toxins displays DNAse I-like activity 11 . Exposure of human cells to these toxins causes cell cycle arrest and cytotoxicity by inducing DNA breaks 11, 12 . Virulence factors often interact closely with host cells at the site of infection to create an environment favorable to colonization. It is unclear whether CDTs that target different anatomical sites also use different host factors for cell intoxication. Notwithstanding their similar overall structure, CDTs from different species diverge in sequence, with subunits A and C being the cell-binding component and the more conserved B subunit the catalytic domain with homology to DNAses 11 ( Fig. 2a) . These differences in sequence likely reflect the lifestyles and anatomical host niches targeted by the bacteria that produce them (Fig. 2b) . The limited sequence conservation of the cell binding subunits may reflect the use of different entry factors. We used PhITSeq to determine whether CDTs of diverse origin and structure use different pathways for entry and intoxication, or whether they also share components. Four different bacterial toxins were produced, each of them causing the characteristic G2/M arrest in HeLa and KBM7 cells (Fig. 2c) . Four pools of 100 million library mutant cells were each treated with a different CDT, surviving cells were isolated 20 d after intoxication and insertions were mapped. The proximity plots and 3a) . The observed enrichment scores, as calculated by comparing mutations in genes before and after selection, were highly significant (P-values between 4 × 10 −6 and 1 × 10 −307 , Fig. 3b ). Among the genes identified were TMEM181 and SGMS1, already found in a haploid screen using E. coli CDT 1 . None of the ten other host factors had been previously implicated in CDT intoxication. These host gene products are unlikely to act as generic entry factors for pathogens because none of them were enriched in any of the other phenotypic screens performed to date, for example, for diphtheria toxin, ricin or reovirus ( Fig. 3b and data not shown) . For most of the newly identified factors, neither their roles in intoxication nor even any other functions were known. With the exception of ERP44, a soluble oxidoreductase that resides in the endoplasmic reticulum (ER) lumen 13 , they all are integral membrane proteins as inferred from their predicted amino acid sequence. They reside either in the plasma membrane and/or in the endomembrane system, including Golgi (GLG1) 14 , ER lumen (ERP44) and transport vesicles (TMED2 and TMED10) 15 . CDTs of different origin require distinct sets of host factors, with sphingomyelin synthase 1 (SGMS1) being the only host factor common to all four screens. E. coli CDT requires the G protein-coupled receptor homolog TMEM181, sphingomyelin synthase 1 (SGMS1), Golgi glycoprotein 1 (GLG1) and the vacuolar ATPase subunit 2 (ATP6V0A2).
A. actinomycetemcomitans CDT shows a similar pattern but does not require TMEM181 and is critically reliant on the presence of a synaptogyrin 2 (SYNGR2), a ubiquitously expressed integral membrane protein 16 . C. jejuni has evolved dependency on a different set of host factors compared to the other CDTs. Besides proteins involved in vesicular transport, three plasma membrane proteins were identified as essential: TMEM127, a familial tumor suppressor gene 17 , GPR107, an uncharacterized G protein-coupled receptor and TM9SF4, linked to resistance to pathogenic Gram-negative bacteria by preventing phagocytosis in Drosophila 18 . These results are consistent with the notion that CDTs from different species have evolved partially overlapping, yet distinct, routes of intoxication. Remarkably, CDTs secreted by bacteria that colonize different anatomical sites may still show very similar host factor requirements (e.g., H. ducreyi and A. actinomycetemcomitans), whereas CDTs from bacteria that occupy similar niches (e.g., E. coli and C. jejuni) can have very distinct requirements. We further investigated ATP6V0A2 to determine whether the genes identified here are also involved in CDT-mediated intoxication in other cell types. Our screen suggests that this v-ATPase subunit is required for intoxication by E. coli CDT, whereas intoxication by CDT derived from C. jejuni appears to be less dependent on this host factor. We treated HeLa cells with concanamycin A, a specific inhibitor of v-ATPase 19 , and exposed them to either E. coli CDT or C. jejuni CDT. Concanamycin treatment abolished the ability of E. coli CDT to induce cell cycle arrest at the G2/M phase of the cell cycle, whereas the action of C. jejuni CDT was not impaired, in agreement with the differential requirement for this host factor suggested by our screens (Supplementary Fig. 2) . Thus, comparative profiling using PhITSeq identified ten novel host factors required for a family of bacterial toxins and provides a solid genetic framework for further study of the molecular mechanisms of host-pathogen interactions. Identification of these host factors now permits examination of their involvement in tissue damage inflicted by CDTs in vivo, at the actual anatomical sites they target.
The PhITSeq approach is scalable and allows precise comparative analyses by using the same well-characterized library of mutants for multiple phenotypic selections. Here we present 12 examples of independent phenotypic screens, not only using different pathogens but also a collection of targeted cancer therapeutics (Fig. 3b) . Each screen Figure 3 Genes linked to different phenotypes. (a) Gene-trap insertions identified in loci essential for CDT intoxication. A color code distinguishes gene-trap insertions that were enriched using distinct CDTs: green, A. actinomycetemcomitans; red, E. coli; blue, C. jejuni; yellow, H. ducreyi. (b) Loci linked to 12 separate phenotypes. Cells were exposed to small-molecule inhibitors of the Bcl2-family (ABT-737), Chk1-kinase activity (AZD7762), Bcr-Abl-activity (imatinib), or DNA methylation (decitabine). Additional phenotypic selections were done using biological agents such as TRAIL, CDTs, diphtheria toxin, ricin toxin and reovirus. Gene-trap insertions in exonic sequences or in the sense orientation of genes were counted per individual selection. The enrichment P-value was calculated for each gene locus by comparing this number to the number of insertions identified in the same locus within the unselected cell population. Each screen resulted in a distinct set of one to eight genes with high significance. These include already known entry factors used by pathogens such as the entry receptor for diphtheria toxin (HBEGF), the reovirus receptor (F11R) and an enzyme involved in carbohydrate synthesis required for ricin entry (MGAT2). It also includes downstream effectors of kinases, for example. CDC25A in a screen with a Chk1 inhibitor or PTPN1 and PTPN12 identified by Bcr-abl inhibition using imatinib. Strong resistance against decitabine was observed in cells containing mutations in deoxycytidine kinase (DCK), the rate-limiting kinase for activation of several nucleoside analogs 20 . 
l e t t e r s yields a select number of hits. In the examples of TRAIL, ABT-737, decitabine, AZD7762, diphtheria toxin and reovirus, each of the hits correspond to established key regulators of the phenotype, including cell surface receptors (HBEGF, F11R), downstream effector molecules (FADD, CASP8) and a drug-metabolizing enzyme (DCK). These findings suggest that these screens are unlikely to be confounded by large numbers of false-positive results. In the case of CDTs, all significant hits are either transmembrane proteins or proteins involved in membrane trafficking events. These might act as toxin receptors or be involved in intracellular trafficking of receptor-toxin complexes. The clusters of insertion sites found in the various selected cell populations are located within genes and are predicted to disrupt gene function, based on their orientation and location. It is therefore likely that the gene-trap insertions directly affect the genes into which they insert, rather than perturbing neighboring genes through action at a distance. Indeed, the retroviral vectors used for mutagenesis themselves lack strong promoter or enhancer sequences, disfavoring the possibility of 'long distance' effects. Our screens are unlikely to identify factors that are either essential for cell viability in the absence of selection or show genetic redundancy (such as the TRAIL receptors). Indeed, essential genes can be recognized by a paucity of sense orientation, gene-trap insertions in the mutagenized unselected cell population. Fig. 3 ). Genes whose disruption severely reduces cell fitness without outright cytolethal effects would be underrepresented in our screens and therefore may fail to reach levels of high significance, even when involved in the phenotype of interest. In contrast to RNA interference-based screens, which can be applied to many cell types, our approach, for now, relies on the use of one particular human near-haploid cell line. Although many cellular phenotypes should be accessible in these cells, the generation or isolation of additional haploid cell types, for example, by reprogramming, would be useful.
A clear example of this is BCR-ABL (Supplementary
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/nbt/index.html. Sequence analysis of the gene-trap insertion sites in the unselected mutagenized cell population. Genomic DNA was isolated from ~40 million cells using QIAamp DNA mini kit (Qiagen) according to manufacturer's protocol. After digestion with NlaIII or MseI, genomic DNA was used as template for a linear PCR (99 cycles) using a 5′-biotinylated primer (5′-GGTCTCCAAATCTCGGTGGAAC-3′) annealing to the GT-GFP genetrap vector. The resulting ssDNA product contains the 5′LTR of the retroviral vector followed by the genomic DNA sequence flanking the insertion site ending at either an NlaIII or MseI restriction site. This product was purified using streptavidin-coated beads (Dynabeads M-280; Invitrogen) and a 5′-phosphorylated and 3′-modified (dideoxycytidine, ddC) ssDNA linker was ligated to the 3′end of the product using a ssDNA ligase (CircLigase II, Epicenter Biotechnologies). The linker (5′-TCGTATGCCGTCTTCTGCTTGACTCAGT AGTTGTGCGATGGATTGATG-3′) contains adaptor sequence II required for sequencing using the Genome Analyzer (Illumina). After ligation the product was purified and used as template for a PCR that adds adaptor sequence I with primers (5′-AATGATACGGCGACCACCGAGATCTGATGGTTCTCTAGCT TGCC-3′) and (5′-CAAGCAGAAGACGGCATACGA-3′). The PCR generates products of different lengths representing the abundance of individual insertion sites present in the sample, which visualizes as a smear on an agarose gel. After column purification (Qiaquick PCR purification kit, Qiagen), 8 pM of the product was sequenced on one lane of an Illumina Model GA2X Genome Analyzer using a custom sequencing primer annealing to the extreme end of the 5′LTR (5′-CTAGCTTGCCAAACCTACAGGTGGGGTCTTTCA-3′), resulting in sequences directly flanking the site of insertion of the gene-trap vector.
Analysis of gene-trap insertions in the unselected mutagenized cell population. The 36-base-pair (bp) sequences in the FASTQ data file were aligned to the human genome (hg18) using Bowtie alignment software 21 . We used stringent criteria to exclude ambiguous alignments by not allowing any mismatches in the full 36-bp sequence and by excluding all sequences that align nonuniquely to the human genome. Of the sequence reads 59% aligned uniquely over the full 36-bp sequence, 33% were excluded because they contained one or more mismatches and 8% were excluded because of nonunique alignment. Using these criteria, we obtained an insertion data table that contains ~900,000 independent insertion sites mapped to the human genome (Supplementary Table 1 ). Based on their position on the human genome, insertion sites were identified as located in genomic regions annotated to contain genes. We further classified these insertions as being in the sense or antisense orientations compared to the gene. This was done by intersecting (based on chromosome intervals) the insertion database with a data table containing the chromosomal coordinates of RefSeq 22 annotated genomic regions retrieved from the UCSC genome table browser database 23 , using BEDTools software 24 . The resulting gene insertion data table contains ~450,000 insertions meeting these criteria (Supplementary Table 2 ).
To determine the percentage of expressed genes that contain insertions, we used gene expression data from KBM7 cells (GEO: GSE7114) 7 . The present/ absent calls of five replicates were summarized, coupled to gene symbol and this table was joined to the gene insertion data table (Supplementary Table 3) . From this table we derive the percentage of expressed (P, present), marginally expressed (M, marginal) and nonexpressed (A, absent) genes that contain insertions. Discrepancies of gene symbol annotation of the Affymetrix platform with the RefSeq data table are indicated and excluded from the analysis.
Treatment of cells for phenotypic enrichments.
For a phenotypic enrichment screen, 100 million cells were incubated with the selection agent. In a typical screen the resistant cells were expanded over the course of ~20 d. When the cells were expanded to 30 million cells, cell debris was removed by multiple wash steps with PBS and genomic DNA was isolated to map the insertion sites. In general the selection agent was present during the course of the experiment. Concentrations used were: diphtheria toxin (Sigma-Aldrich) 400 ng/ml, ricin (Vector Laboratories) 40 ng/ml, ABT-737 (Selleck Chemicals) 15 µM, AZD7762 (Selleck Chemicals) 250 nM, and decitabine (Tocris Bioscience) 15 µM. Imatinib was added at 2 µM for 4 d, after which it was further diluted to 600 nM followed by a 20 d incubation. Recombinant TRAIL (Sigma-Aldrich) was added at a concentration of 1 µg/ml for 7 d, after which it was diluted twofold and surviving cells were expanded. The cytolethal distending toxins were produced as described below. The following dilutions were used for the screen: CDT E. coli 0.4 µl/ml, CDT C. jejuni 2.0 µl/ml, CDT H. ducreyi 0.05 µl/ml and A. actinomycetemcomitans 0.01 µl/ml.
Cloning and production of cytolethal distending toxins. E. coli CDT.
The construct for the full operon of E. coli CDT was generously provided by J. Kaper (pDS7.96) 25 . A starter culture of E. coli BL21 cells transformed with this plasmid was used to inoculate 500 ml of sterile M9 minimal media (Sigma) supplemented with 1% (wt/vol) glucose. After 21 h at 37 °C with vigorous shaking, the supernatant was filter sterilized (0.22 µm pore size filter). The filtrate was concentrated using a Centricon-Plus 70 (Millipore) with a cut-off filter of 30 kDa to a final volume of 5 ml. The buffer was exchanged to PBS using a PD10 desalting column (GE Healthcare Life Sciences) and filter sterilized.
A. actinomycetemcomitans CDT. The operon sequence between subunits CdtA and CdtC was amplified from genomic DNA of Aggregatibacter actinomycetemcomitans (ATCC 700685D-5) using the following forward: 5′-ATCTAAGGAGAGGTACAATGAAA-3′ and reverse 5′-TTAGC TACCCTGATTTCTCC-3′ primers. The PCR product was purified from agarose gel using a QIAquick Gel Extraction Kit (Qiagen) and cloned into the pGemTeasy vector (Promega). A clone displaying the 5′ end in the orientation of the T7 promoter was used as template to introduce a Shine-Delgarno sequence upstream of the initial methionine by Quikchange II Site-Directed Mutagenesis (Stratagene) and the following primer: 5′-GGGCCCGACGTC GCTTAACTTTAAGAAGGAGCTCCGGCCGCCATGG-3′. A starter culture of E. coli BL21 (DE3) transformed with the resulting construct was used to inoculate 250 ml M9 minimal media (Sigma) supplemented with 1% (wt/vol) glucose. When the culture reached an optical density of ~0.4 at 600 nm, it was induced with (IPTG 0.5 mM) and incubated for 5 h at 37 °C with vigorous shaking. The culture was centrifuged at 10,000g for 15 min in a Sorvall RC6 PLUS centrifuge (SLA1500 rotor). The resultant supernatant was filtered and concentrated following the protocol described for E. coli CDT.
C. jejuni CDT. Individual toxin subunits were amplified from genomic DNA (ATCC 43432D-5), thereby removing secretion signal sequences, using the following primers: CdtA 5′-GCGCCATGGGATGTTCTTCTAAATTTG-3′ and 5′-CGCCTCGAGTCGTACCTCTCCTTGGCG-3′, CdtB 5′-GCGCCAT GGGAAATTTAGAAAATTTTA-3′ and 5′-CGCCTCGAGAAATTTTCTAA AATTTAC-3′, CdtC 5′-GCGCCATGGGAACTCCTACTGGAGATT-3′ and 5′-CGCCTCGAGTTCTAAAGGGGTAGCAGC-3′, and 5′-CGCCTCGAGG CTACCCTGATTTCTTCG-3′. Each subunit was cloned into pET28(+) vector (Novagen) between the NcoI and XhoI restriction sites to equip each subunit with a C-terminal His6 tag. Individual subunits were expressed separately in E. coli BL21 grown in TB medium (Terrific Broth, Sigma) supplemented with 1% glycerol at 37 °C under agitation (220 r.p.m., Innova 5000 Gyrotory Tier Shaker, New Brunswick Scientific). Expression was induced in mid-log growth phase with 0.3 mM IPTG (isopropyl-β-d-1-thiogalactopyranoside, Sigma). After an expression time of 5 h, the three CDT subunit expression cultures were pooled, centrifuged (6,000g, 15 min, Avanti J-E Centrifuge, Beckman Coulter) and pellets freeze-thawed. Proteins were solubilized under denaturing conditions at 37 °C (8 M urea, 20 mM HEPES (N- piperazine-N-[2-ethanesulphonic acid]) pH 7.5, 200 mM NaCl, 0.1% (vol/vol) TritonX-100, 2.5 mM dithiothreitol (DTT), 2 mM ethylenediaminetetraacetic acid (EDTA), purified at 4 °C using nickel chelating affinity resin (Ni-NTA agarose, Qiagen) and eluted with 0.3 M imidazole. CDT was co-refolded by stepwise dilution of 8 M urea to 1 M urea with 20 mM HEPES pH 7.5, 200 mM NaCl, 2.5 mM DTT, 2 mM (EDTA), protease inhibitor (Complete Mini, Roche) buffer at 4 °C on a stirring plate. Following a second nickel chelating affinity resin purification and concentration step (Amicon Ultra Centrifugal filter units, MWCO = 30 kDa, Millipore), the holotoxin was further purified with size exclusion chromatography (Äkta FPLC gel filtration system, HiLoad 16/60 Superdex 200 column, GE Healthcare). Protein-containing fractions were tested for toxicity by cell cycle analysis of intoxicated HeLa cells. Toxic fractions were pooled and concentrated.
H. ducreyi CDT. Individual toxin subunits were amplified from genomic DNA (ATCC 700724D-5), thereby removing secretion signal sequences, using the following primers: CdtA 5′-GCGCCATGGGATGTTCATCAAATCAAC-3′ and 5′-CGCCTCGAGATTAACCGCTGTTGCTTC-3′, CdtB 5′-GCGCCAT GGGAAACTTGAGTGACTTCA-3′ and 5′-CGCCTCGAGGCGATCACGA ACAAAACT-3′, CdtC 5′-GCGCCATGGGAAGTCATGCAGAATCAA-3′ and 5′-CGCCTCGAGGCTACCCTGATTTCTTCG-3′. Cloning and production of the toxin was performed similar to the protocol described for C. jejuni CDT.
Sequencing of gene-trap insertion sites in phenotypically enriched populations. The lower complexity of selected cell populations allowed the insertion sites to be mapped by inverse PCR reaction. Genomic DNA was isolated from ~30 million cells using QIAamp DNA mini kit (Qiagen) according to manufacturer's protocol. After digestion with MseI or NlaIII, DNA was ligated using T4 DNA ligase to circularize the fragments. After column purification (Qiaquick PCR purification kit, Qiagen), a PCR was performed using outward facing primers annealing internally in the gene-trap vector, thereby introducing the Illumina adaptor sequences I and II. The primers used for ligated DNA digested with NlaIII were (5′-AATGATACGGCGACCACCG AGATCTGATGGTTCTCTAGCTTGCC-3′ and 5′-CAAGCAGAAGACGG CATACGACCCAGGTTAAGATCAAGGTC) and for ligated DNA digested with MseI were (5′-AATGATACGGCGACCACCGAGATCTGATGGTTC TCTAGCTTGCC-3′ and 5′-CAAGCAGAAGACGGCATACGACGTTCTG TGTTGTCTCTGTCTG). After column purification, 8 pM of the products was sequenced on one lane of an Illumina Model GA2X Genome Analyzer using a custom sequencing primer annealing to the extreme end of the 5′LTR (5′-CTAGCTTGCCAAACCTACAGGTGGGGTCTTTCA-3′).
Identification of unique insertion sites in the phenotypically enriched populations. The 36-base-pair (bp) sequences in the FASTQ data file were mapped to the human genome (hg18) using Bowtie alignment software 21 . Because the complexity of insertions is significantly lower in the selected pools compared to the unselected pools and because PCR amplification is not unbiased, some individual insertion sites are sequenced in very high frequency. An unwanted consequence of this is the appearance of sequencing errors. Stringent criteria were used to identify unique insertion sites. No mismatches were allowed in the 36-bp sequence and the sequence should uniquely align to the human genome even when 1 or 2 mismatches are allowed. If two insertions align 1 or 2 base pairs apart, only 1 is retained. For each selection a data table was produced containing these insertion sites (Supplementary Tables 4-16 ). To distinguish genomic regions with a high density of insertions, we define the proximity index for a given insertion as the inverse value of the average distances with its neighboring insertion sites. The inverse value is calculated from the average distance (in base pairs) between the given insertion and the two neighboring upstream insertions and the two next downstream insertion sites. This method of analysis pinpoints insertion-rich regions in phenotypic screens and includes all insertions (sense and antisense). It provides a graphical illustration of insertion site clustering and thereby allows nonannotated elements also to be identified.
An alternative method of analysis focuses on the insertions in a given screen that are present in genes and compares these to the unselected population. To create a control data set, the FASTQ data file for the unselected population described above was analyzed using the same criteria as for the selected pools. The total number of insertions in genes and the number of insertions per individual gene were counted by intersecting the insertions with the data table containing chromosomal coordinates of RefSeq-annotated genes. If an insertion was located in a genomic region shared by multiple transcripts of the same gene, it only counted once. For a given screen, the number of inactivating mutations (= sense orientation or present in exon) per individual gene was counted as well as the total number of inactivating insertions for all genes. Enrichment of a particular gene in a particular screen was calculated by comparing how often that gene was mutated in the screen compared to how often the genes carries an insertion in the control data set (Supplementary Table 17 ). For each gene a P-value (corrected for false-discovery rate) was calculated using the one-sided Fisher exact test run in the R software environment. In some cases the P-value was lower than the R software could report. In these cases the numerical value was set to the smallest nonzero normalized floating-point number R could report (~1 × 10 −307 ).
